Achillion prices shares to net $118.5m for HCV drug combo development
This article was originally published in Scrip
Executive Summary
Achillion Pharmaceuticals priced 15 million shares of common stock at $8.40 per share for net proceeds of $118.5 million to advance its lead hepatitis C virus (HCV) drug candidates – sovaprevir, ACH-3102 and ACH-2684 – into late-stage development.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.